SEOM clinical guidelines for the management of metastatic breast cancer 2013

被引：0
作者：
A. Llombart Cussac
J. de la Haba Rodríguez
A. Ruiz Simón
I. Álvarez López
J. Cortés Castán
机构：
[1] Hospital Arnau de Vilanova,Servicio de Oncología Médica
[2] Hospital Universitario Reina Sofía,Servicio de Oncología Médica
[3] Instituto Valenciano de Oncología,Servicio de Oncología Médica
[4] Hospital de Donostia,Servicio de Oncología Médica
[5] Hospital General Vall d’Hebrón,Servicio de Oncología Médica
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Metastatic; Breast; Cancer; Treatment; ER; HER2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with metastatic breast cancer should be offered comprehensive and personalized medical attention including, but not limited to, psychosocial, supportive and symptom-related interventions. A large number of treatment options are available and several prognostic and predictive factors are useful to identify the best therapeutic options individually.
引用
收藏
页码：1004 / 1010
页数：6
相关论文
共 94 条
  • [1] Alvarez-Lopez I(2010)SEOM clinical guidelines for the treatment of metastatic breast cancer Clin Transl Oncol. 12 719-723
  • [2] de la Haba-Rodríguez J(2012)1st International consensus guidelines for advanced breast cancer (ABC 1) Breast. 21 242-252
  • [3] Ruiz-Simón A(2009)Locally recurrent or metastatic breast cancer: ESMO. Clinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 4 15-18
  • [4] Bellet Ezquerra M(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 520-529
  • [5] Calvo Martínez L(2012)The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 23 1378-1386
  • [6] García Estévez L(2012)Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study Breast Cancer Res Treat 136 503-511
  • [7] Cardoso F(2012)FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer J Clin Oncol 30 1919-1925
  • [8] Costa A(2012)Combination anastrozole and fulvestrant in metastatic breast cancer N Engl J Med 367 435-444
  • [9] Norton L(2011)The role of chemotherapy and targeted agents in patients with metastatic breast cancer Eur J Cancer 47 S38-S47
  • [10] Cameron D(2011)RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer J Clin Oncol 29 1252-1260
12345678910